Latest News & Features
Americas
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification. 8 April 2014
Americas
Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone. 8 April 2014
Asia
Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed. 7 April 2014
Americas
Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US. 3 April 2014
Americas
Cooley LLP has recruited Ivor Elrifi and Heidi Erlacher to the patent counselling team serving the life sciences and technology sectors. 3 April 2014
Americas
Schiff Hardin LLP has expanded its IP group with the hiring of Imron Aly as a partner. 2 April 2014
Americas
The US Court of Appeals for the Federal Circuit has reversed a lower court decision that found Actavis’s generic version of Shire’s ulcerative colitis drug Lialda (mesalamine) infringes US patent 6,773,720. 2 April 2014
Americas
The US District Court for the Southern District of Indiana has upheld a patent covering Eli Lilly’s second biggest drug Alimta (pemetrexed disodium), after a challenge by Teva’s US pharmaceutical arm. 1 April 2014
Americas
The US Supreme Court has agreed to hear Teva’s appeal against a Federal Circuit decision that invalidated a patent covering its $4.3 billion-a-year Copaxone (glatiramer acetate) drug, allowing Sandoz, Mylan and Natco to produce generic versions. 1 April 2014
Asia
Strand Life Sciences’ ‘virtual’ liver could cut the failure rate of drug development by giving researchers a clearer idea which of the potential drugs are unlikely to work. How does the Bangalore-based company protect and license its technology? 31 March 2014